The findings implicate AMPK as a critical regulator of YAP/TAZ signaling and HSC inactivation and highlight AMPK activation as a therapeutic target for the treatment of hepatic fibrosis. This evidence concerns the gene PRKAA1 and Hepatic fibrosis.